| Literature DB >> 31800721 |
Joan Costa-Mateu1, Diego Fernández-Rodríguez1, Kristian Rivera1, Juan Casanova1, Patricia Irigaray1, Marta Zielonka1, Eduardo Pereyra-Acha1, Albina Aldomá1, Fernando Worner1.
Abstract
BACKGROUND: Coronary angiography with two catheters is the traditional strategy for diagnostic coronary procedures. TIG I catheter permits to cannulate both coronary arteries, avoiding exchanging catheters during coronary angiography by transradial access.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31800721 PMCID: PMC7020970 DOI: 10.5935/abc.20190232
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Figure 1Design of TIG I and Judkins catheters and cannulation of the coronary arteries. RCA: right coronary artery; LCA: left coronary artery.
Figure 2Study Flowchart.
Baseline clinical characteristics
| Total procedures | One-catheter strategy | Two-catheter strategy | p-value | |
|---|---|---|---|---|
| Age, (years), mean (SD) | 67.3 (11.8) | 67.5 (12.1) | 67.2 (11.6) | 0.695 |
| Female gender, n (%) | 611 (31.3%) | 82 (32.5%) | 529 (31.1%) | 0.645 |
| BMI, (kg/m2), mean (SD) | 28.0 (5.3) | 28.1 (4.8) | 28.0 (5.4) | 0.657 |
| Hypertension, n (%) | 1443 (73.9%) | 187 (74.2%) | 1256 (73.8%) | 0.858 |
| Dyslipidemia, n (%) | 1096 (56.1%) | 142 (56.3%) | 954 (56.1%) | 0.861 |
| Diabetes mellitus, n (%) | 701 (35.9%) | 98 (38.9%) | 603 (35.4%) | 0.288 |
| Non-smoker, n (%) | 304 (15.6%) | 39 (15.5%) | 265 (15.6%) | |
| Previous smoker, n (%) | 486 (24.9%) | 56 (22.2%) | 430 (25.3%) | |
| Current smoker, n (%) | 1160 (59.5%) | 157 (62.3%) | 1003 (59.1%) | |
| Previous MI, n (%) | 246 (12.6%) | 27 (10.7%) | 219 (12.9%) | 0.426 |
| Previous PCI, n (%) | 318 (16.3%) | 40 (15.9%) | 278 (16.3%) | 0.675 |
| Family history of ischemic heart disease, n (%) | 75 (3.8%) | 11 (4.4%) | 64 (3.8%) | 0.669 |
| Previous stroke, n (%) | 65 (3.3%) | 6 (2.4%) | 59 (3.5%) | 0.457 |
| Chronic kidney disease, n (%) | 223 (11.4%) | 33 (13.1%) | 190 (11.2%) | 0.468 |
| Creatinine (mg/dL), mean (SD) | 1.15 (0.93) | 1.07 (0.59) | 0.647 |
SD: standard deviation; BMI: body mass index; MI: myocardial infarction; PCI: percutaneous coronary intervention.
Procedural indications and angiographic characteristics
| Total procedures | One-catheter strategy (n = 252) | Two-catheter strategy (n = 1,701) | p-value | |
|---|---|---|---|---|
| Chronic ischemic heart disease, n (%) | 610 (31.2%) | 74 (29.4%) | 536 (31.5%) | |
| Acute coronary syndrome, n (%) | 615 (31.5%) | 77 (30.6%) | 538 (31.6%) | |
| Valvular heart disease, n (%) | 372 (19.0%) | 49 (19.4%) | 323 (19.0%) | |
| Myocardiopathy, n (%) | 272 (17.1%) | 43 (17.1%) | 229 (13.5%) | |
| Other, n (%) | 84 (4.3%) | 9 (3.6%) | 75 (4.4%) | |
| Left main coronary artery diseased, n (%) | 155 (7.9%) | 21 (8.3%) | 134 (7.9%) | 0.803 |
| One vessel, n (%) | 634 (32.5%) | 83 (32.9%) | 551 (32.4%) | |
| Two vessels, n (%) | 294 (15.1%) | 32 (12.7%) | 262 (15.4%) | |
| Three vessels, n (%) | 234 (12.0%) | 25 (9.9%) | 209 (12.3%) |
Endpoints
| Total procedures | One-catheter strategy (n = 252) | Two-catheter strategy | p-value | |
|---|---|---|---|---|
| Volume of contrast, (mL), median (IQR) | 90 (62-118) | 77 (60-105) | 92 (64-120) | < 0.001 |
| Radial spasm, n (%) | 176 (9.0%) | 13 (5.2%) | 163 (9.3%) | 0.022 |
| Access crossover, n (%) | 92 (4.7%) | 9 (3.6%) | 83 (4.9%) | 0.360 |
| Supplemental catheters, n (%) | 252 (12.9%) | 40 (15.9%) | 212 (12.5%) | 0.132 |
| Direct costs, (€/procedure), median (IQR) | 169 (158-182) | 149 (140-160) | 171 (160-183) | < 0.001 |
| DAP, (mGy.m2), median (IQR) | 3685 (2408-5695) | 3488 (2556-5369) | 3711 (2393-5762) | 0.831 |
| Air kerma, (mGy), median (IQR) | 630 (420-964) | 582 (407-917) | 641 (424-974) | 0.165 |
| Fluoroscopy time, (min), median (IQR) | 4.7 (2.8-8.3) | 3.9 (2.2-8.0) | 4.8 (2.9-8.3) | 0.001 |
IQR: interquartile range; SD: standard deviation; DAP: dose-area product.
| MATERIAL | UNIT PRICE |
|---|---|
| Catheter TIGER I RH-5TIG110M Radiofocus Optitorque® 5F; Terumo Europe N.V., Leuven, Belgium | 17.45 € |
| Catheter 534518T INFINITI® 5F Judkins Left; Cordis Corporation, Cashel, Ireland | 17.95 € |
| Catheter 534523T INFINITI® 5F Judkins Right; Cordis Corporation, Cashel, Ireland | 17.95 € |
| Xenetix 350 100mL/Bottle; Guerbert Group, Villepinte, France | 35.09 € |
| Sheath RT-R50G10PQ RADIFOCUS® INTRODUCER II 5 Fr or 6 Fr; Terumo Europe N.V., Leuven, Belgium | 10.71 € |
| Exchange Guidewire M001491031 Starter "J" Curved Fixed Core 0.035 x 260 cm; Boston Scientific, Marlborough, MA, USA | 8.40 € |
| Sterile Pack CombiSet® REF 266315; Hartmann, Heidenheim, Germany | 40.31 € |
| Injector control AngioTouch® Kit; ACIST Medical Systems, Inc, Eden Prairie, MN, USA | 38.00 € |
| Mepivacaine 2%; BBraun, Melsungen, Germany | 0.87 € |
| Heparin 1%; Hospira Prod. Farm. y Hosp S.L, Alcobendas, Spain | 1.89 € |
| Verapamil hydrochloride 2.5 mg/mL; Mylan, Canonsburg, PA, USA | 0.59 € |